Cost and Cost Effectiveness of Vaginal Progesterone Gel in Reducing Preterm Birth: An Economic Analysis of the PREGNANT Trial
- 287 Downloads
Preterm birth (PTB) is a costly public health problem in the USA. The PREGNANT trial tested the efficacy of vaginal progesterone (VP) 8 % gel in reducing the likelihood of PTB among women with a short cervix.
We calculated the costs and cost effectiveness of VP gel versus placebo using decision analytic models informed by PREGNANT patient-level data.
PREGNANT enrolled 459 pregnant women with a cervical length of 10–20 mm and randomized them to either VP 8 % gel or placebo. We used a cost model to estimate the total cost of treatment per mother and a cost-effectiveness model to estimate the cost per PTB averted with VP gel versus placebo. Patient-level trial data informed model inputs and included PTB rates in low- and high-risk women in each study group at <28 weeks gestation, 28–31, 32–36, and ≥37 weeks. Cost assumptions were based on 2010 US healthcare services reimbursements. The cost model was validated against patient-level data. Sensitivity analyses were used to test the robustness of the cost-effectiveness model.
The estimated cost per mother was $US23,079 for VP gel and $US36,436 for placebo. The cost-effectiveness model showed savings of $US24,071 per PTB averted with VP gel. VP gel realized cost savings and cost effectiveness in 79 % of simulations.
Based on findings from PREGNANT, VP gel was associated with cost savings and cost effectiveness compared with placebo. Future trials designed to include cost metrics are needed to better understand the value of VP.
Watson Pharmaceuticals (now Actavis) is the sponsor of this economic analysis. The NDA for Prochieve® was transferred to Watson Pharmaceuticals from Columbia Laboratories, Inc. during the course of this work.
Pizzi, Seligman, Baxter, Jutkowitz, and Berghella have no conflicts of interest to disclose. Contributions of individual authors are as follows: Pizzi: conception, design, analysis, drafting and critical revision of the manuscript, manuscript approval, and guarantor of work; Seligman, Baxter, and Berghella: conception, design, critical revision of the manuscript, manuscript approval; Jutkowitz: conception, analysis, critical revision of manuscript, manuscript approval.
- 2.March of Dimes, PMNCH, Save the Children, WHO. In: Howson CP, Kinney MV, Lawn JE, editors. Born too soon: the global action report on preterm birth. Geneva: World Health Organization; 2012. http://www.who.int/pmnch/media/news/2012/201204_borntoosoon-report.pdf. Accessed 19 Nov 2012.
- 3.Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2010. National Vital Statistics Reports. 2011;60(2).Google Scholar
- 5.Institute of Medicine (US) Committee on Understanding Premature Birth and Assuring Healthy Outcomes. Societal costs of preterm birth. In: Behrman RE, Butler AS, editors. Preterm birth: causes, consequences, and prevention. Washington, DC: National Academic Press; 2007. p. 389–439.Google Scholar
- 6.Preterm Birth: Causes, Consequences, and Prevention. Consensus Panel Report. Institute of Medicine; 2006. http://iom.edu/Reports/2006/Preterm-Birth-Causes-Consequences-and-Prevention.aspx; Chapter 12 (IHC data). Accessed 31 Jan 2012.
- 14.Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188:419–24.PubMedCrossRefGoogle Scholar
- 17.U.S. Food and Drug Administration. Reproductive Health Drugs Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM292006.pdf. Accessed 5 Mar 2012.
- 18.International classification of diseases and related health problems. 10th revision. Geneva: World Health Organization; 1992.Google Scholar
- 19.United States Department of Labor. Bureau of Labor Statistics. Consumer Price Index (Medical Services Component). Consumer Price Index Detailed Report: Data for December 2011; 2011. http://www.bls.gov/cpi/cpid1112.pdf. Accessed 13 Mar 2012.
- 20.National Fee Analyzer. Ingenix; 2010.Google Scholar
- 21.Crinone. RED BOOK™ Drug References. Horsham: Thomson Reuters; 2010.Google Scholar
- 22.Expert DRG. A comprehensive guidebook to the DRG classification system. Salt Lake City: Ingenix; 2011.Google Scholar
- 23.Agency for Healthcare Research and Quality HCUPNet. DRG 775 Normal newborn, 2009HCUPNet database, Rockville. http://www.hcupnet.arhq.gov. Accessed 1 Jan 2013.
- 24.Consumer Price Index Detailed Report, Table 1. December 2010, U.S. Bureau of Labor Statistics. http://www.bls.gov/cpi/#tables. Accessed 31 Jan 2012.
- 28.Centers for Disease Control and Prevention. Department of Health and Human Services. PRAMS and Preterm Delivery; 2006. http://www.cdc.gov/reproductivehealth/ProductsPubs/PDFs/Preterm%20Delivery%20FS.pdf. Accessed 10 Jan 2013.
- 29.Progesterone Gel 8% NDA 22-139. Presentation to the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration, Columbia Laboratories, Inc.; 2012.Google Scholar